KR20230078997A - 병용 암 요법에서의 dhodh 저해제 화합물의 용도 - Google Patents

병용 암 요법에서의 dhodh 저해제 화합물의 용도 Download PDF

Info

Publication number
KR20230078997A
KR20230078997A KR1020237004006A KR20237004006A KR20230078997A KR 20230078997 A KR20230078997 A KR 20230078997A KR 1020237004006 A KR1020237004006 A KR 1020237004006A KR 20237004006 A KR20237004006 A KR 20237004006A KR 20230078997 A KR20230078997 A KR 20230078997A
Authority
KR
South Korea
Prior art keywords
lymphoma
compound
pharmaceutically acceptable
formula
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237004006A
Other languages
English (en)
Korean (ko)
Inventor
존 코코
브랜든 니콜라이
Original Assignee
르 라보레또레 쎄르비에르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 르 라보레또레 쎄르비에르 filed Critical 르 라보레또레 쎄르비에르
Publication of KR20230078997A publication Critical patent/KR20230078997A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237004006A 2020-08-27 2021-08-26 병용 암 요법에서의 dhodh 저해제 화합물의 용도 Pending KR20230078997A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063070984P 2020-08-27 2020-08-27
US63/070,984 2020-08-27
PCT/US2021/047778 WO2022047051A1 (en) 2020-08-27 2021-08-26 Use of a dhodh inhibitor compound in combination cancer therapy

Publications (1)

Publication Number Publication Date
KR20230078997A true KR20230078997A (ko) 2023-06-05

Family

ID=78000775

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237004006A Pending KR20230078997A (ko) 2020-08-27 2021-08-26 병용 암 요법에서의 dhodh 저해제 화합물의 용도

Country Status (9)

Country Link
US (1) US20230285365A1 (https=)
EP (1) EP4203950B1 (https=)
JP (1) JP7734742B2 (https=)
KR (1) KR20230078997A (https=)
CN (1) CN116847874A (https=)
BR (1) BR112023003493A2 (https=)
CA (1) CA3190511A1 (https=)
ES (1) ES3063941T3 (https=)
WO (1) WO2022047051A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211462T1 (hr) 2017-04-24 2021-12-24 Aurigene Discovery Technologies Limited Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze
TWI818954B (zh) 2018-02-20 2023-10-21 法商施維雅藥廠 三取代之苯并三唑衍生物的使用方法
JOP20210147A1 (ar) * 2018-12-21 2023-01-30 Les Laboratoires Servier Sas صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57962B1 (sr) 2013-02-25 2019-01-31 Aurigene Discovery Tech Ltd Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US20180369206A1 (en) * 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
HRP20211462T1 (hr) * 2017-04-24 2021-12-24 Aurigene Discovery Technologies Limited Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze
TWI818954B (zh) 2018-02-20 2023-10-21 法商施維雅藥廠 三取代之苯并三唑衍生物的使用方法
WO2020109625A1 (en) * 2018-11-30 2020-06-04 Fondazione Centro San Raffaele Combined treatment of primary central nervous system lymphoma
JOP20210147A1 (ar) 2018-12-21 2023-01-30 Les Laboratoires Servier Sas صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه

Also Published As

Publication number Publication date
CN116847874A (zh) 2023-10-03
US20230285365A1 (en) 2023-09-14
WO2022047051A1 (en) 2022-03-03
JP7734742B2 (ja) 2025-09-05
CA3190511A1 (en) 2022-03-03
EP4203950C0 (en) 2026-02-18
ES3063941T3 (en) 2026-04-21
EP4203950A1 (en) 2023-07-05
BR112023003493A2 (pt) 2023-04-11
JP2023540206A (ja) 2023-09-22
EP4203950B1 (en) 2026-02-18

Similar Documents

Publication Publication Date Title
KR20230078997A (ko) 병용 암 요법에서의 dhodh 저해제 화합물의 용도
US7678391B2 (en) Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US10946000B2 (en) Method for treating cancer with combination therapy
JP2021512105A (ja) 消化管間質腫瘍の治療のための併用療法
EP2830664A1 (en) Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
WO2021262881A1 (en) Use of a dhodh inhibitor compound in combination cancer therapy
KR20250013187A (ko) 니로가세스타트를 사용한 치료
TW201817425A (zh) 用於治療非酒精性脂肪肝疾病之醫藥組成物及方法
US20220031657A1 (en) Pharmaceutical combination comprising lsz102 and ribociclib
US8906357B2 (en) Treatment of multiple sclerosis with masitinib
FR3056108B1 (fr) Utilisation des harringtonines dans le traitement cancer du sein, notamment triple-negatif
EA049299B1 (ru) Применение соединения-ингибитора на основе dhodh в комбинированной терапии рака
Butty et al. Chronic lymphocytic leukemia–associated membranous glomerulopathy: Remission with fludarabine
US6277846B1 (en) Use of platelet activating factor antagonists as anti-pruritic agents
US20240165280A1 (en) Methods for treatment of cancers
AU2024304092A1 (en) Use of akt inhibitor in preparation of drug for preventing or treating breast cancer
KR20250055565A (ko) 티로신 키나아제 억제제 보도바티닙을 사용하여 만성 골수성 백혈병을 치료하는 방법
US20240075041A1 (en) Treatment of eosinophilic disorders with avapritinib
KR20260010420A (ko) 암 치료를 위한 parp1 억제제 및 선택적 에스트로겐 분해제의 병용
CN119486741A (zh) 1,3,5-三嗪衍生物的药物组合
EA052412B1 (ru) Комбинированная терапия для лечения мастоцитоза

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230202

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240823

Comment text: Request for Examination of Application